68 results about "Connexin" patented technology

The present disclosure generally relates to compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, preferably for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

The present disclosure generally relates to compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to define the effect of connexin43 in the cardiac hypertrophy process caused by myocardial cell hypertrophy induced by pathological matrix stiffness and pressure overload, the invention provides application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the application disclosed by the invention, the Connexin43 gene is found to be used as a potential target for preventing or treating myocardial fibrosis for the first time, and a myocardial cell hypertrophy process induced by pathological matrix hardness and a myocardial hypertrophy process caused by overload of pressure can be relieved by knocking down the expression of the Connexin43 gene or inhibiting the semi-channel activity of the Connexin43. Therefore, the inhibitor targeting the Connexin43 gene can be used for preparing the medicine for preventing or treating the myocardial fibrosis, and a new way is provided for treating the myocardial fibrosis.

To provide compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.SOLUTION: Provided herein are compositions and methods for treating a disease or condition associated with opening (e.g., excessive or prolonged opening) of Cx43 hemichannels, such as inflammatory diseases or conditions and neurodegenerative diseases, e.g., spinal cord injury, Alzheimer's disease, osteoarthritis.SELECTED DRAWING: None

The invention discloses a method for promoting ovulation of sexual maturity zebrafish by using Gap27, and relates to the technical field of artificial breeding of fish, a gap connecting protein inhibitor Gap27 is applied to ovulation induction of zebrafish, an intercellular communication network in follicles is accurately intervened, the problem of asynchronous ovulation is solved, and in the final stage of maturation of oocytes, ovulation of sexual maturity zebrafish is promoted. Close substance and information exchange is carried out among follicular granule cells through a gap connecting channel formed by connecting protein Cx43, and Gap27 is used as a specific peptide fragment, can simulate an extracellular ring structure of Cx43, and competitively binds with Cx43 on an adjacent cell membrane, so that formation and functions of the gap connecting channel are physically blocked, and the follicular granule cells are separated from each other. When ovarian tissues of sexually mature female fish are exposed in a Gap27 solution, the transmission of inhibitory signals from granular cells to oocytes can be effectively interrupted, the rupture of nuclear membranes of the cells is promoted, and the final maturation process is completed.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine nano preparation and application thereof in preparation of a medicine for preventing / treating PM2.5 induced lung injury. The invention provides a traditional Chinese medicine nano preparation. The traditional Chinese medicine nano preparation comprises nobiletin, formononetin and a carrier. According to the traditional Chinese medicine nano preparation, the nobiletin and the formononetin are entrapped in the carrier to form the nano particles with uniform particle size and good dispersity, so that the problems of poor water solubility and low bioavailability of the medicine can be effectively improved, the lung targeted delivery is enhanced, and the residence time of the medicine in the lung is prolonged. According to the traditional Chinese medicine nano preparation, the expression of ZO-1, OCLN, E-cad and other connexins is remarkably improved by inhibiting the EGFR pathway, the alveolar epithelial barrier structure and function are protected, and the inflammatory response and oxidative stress induced by PM2.5 are relieved, so that the lung injury induced by PM2.5 is effectively prevented and treated.

The present invention includes novel molecules and methods of using an amphiphilic kanamycin molecule having substitutions at the O-4″, O-6″, or O-4″ and O-6″ positions having reduced antimicrobial activity for targeting Connexin Hemichannels.

The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

This invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The invention further relates to the use of the AAV vector in the treatment of hereditary hearing loss.

The present disclosure provides compositions and methods of treating osteoarthritis such as osteoarthritis in a subject. The method comprises blocking the opening of Cx43 hemichannel in chondrocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

Compositions and methods for targeting connexin hemichannels are provided. Specifically, a monoclonal antibody is provided that comprises the heavy chain amino acid sequence of SEQ ID NO:2, SEQ ID NO:6, or SEQ ID NO:10 and the light chain amino acid sequence of SEQ ID NO:4. Also provided are methods for detecting the presence, levels, and activity of total and cell surface Cx43 hemichannels using the monoclonal antibody, and methods for identifying compounds, conditions, and / or treatments that open connexin hemichannels.

The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, optionally for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

Methods for identifying compounds that positively regulate connexin 43 hemichannels.

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding a connexin 26 (CX26). The invention also relates to the use of said AAV vector in the treatment of hereditary hearing loss.

The present invention relates to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, in rescuing or restoring retinal function, rescuing or restoring retinal structure, and / or rescuing or restoring choroidal structure and / or function in chronic retinal disorders and other disorders.

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a myocardial targeted engineered extracellular vesicle as well as a preparation method and application thereof. The invention provides an engineered extracellular vesicle. The engineered extracellular vesicle is an engineered extracellular vesicle subjected to overexpression modification of gap junction protein alpha 1; the amino acid sequence of the gap connecting protein alpha 1 is shown as SEQ ID NO. 1. The engineered extracellular vesicles are modified by expression gap connecting protein alpha1, and compared with a control, the engineered extracellular vesicles modified by the gap connecting protein alpha1 are more ingested by myocardial cells, have higher heart targeting performance and can provide targeting drug carriers for patients with heart diseases. The invention provides a new drug research and development approach and means for clinical treatment of heart failure or myocardial injury, also provides a heart targeted modification tool for industrial research and development and basic scientific research users, and has very important medicinal value.

The present invention relates to the use of a direct antibody, with a high degree of affinity and specificity, against the extracellular domain of the hemichannels formed by connexin 26 (Cx26, encoded by GJB2), connexin 30 (Cx30, encoded by GJB6) and / or connexin 32 (Cx32, encoded by GJB1), to treat brain tumours and epilepsy correlated thereto or to reduce or inhibit the development thereof.

The invention relates to a connexin-related kinase 1 (AAK1) inhibitor of a compound shown in a general formula (I), a preparation method thereof and application of the connexin-related kinase 1 (AAK1) inhibitor in medicine.

The present invention provides humanized monoclonal antibodies that recognize human connexin 2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry a cytotoxic load and do not interact with the Fc gamma receptor. The invention further provides pharmaceutical compositions comprising said antibodies and methods of their use in cancer immunotherapy.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to clarify the effect of pan-connexin1 in the cardiac hypertrophy process caused by overload of pressure, the invention provides application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the invention, it is found for the first time that Pannexin1 is an effective target spot for treating myocardial hypertrophy caused by pressure overload, and an expression inhibitor for inhibiting Pannexin1 by targeting the target spot can be used for preparing drugs for treating myocardial hypertrophy caused by pressure overload. Therefore, the invention provides the application of the inhibitor targeting the Pannexin1 gene in preparation of the medicine for preventing or treating the myocardial fibrosis, and a new treatment mode is provided for treatment of the myocardial fibrosis.

The invention discloses a method for increasing the yield of astaxanthin in phaffia rhodozyma by using a synergistic gene expression strategy. Firstly, the invention relates to application of a non-homologous terminal connection protein gene and an iron reductase gene in improving the yield of astaxanthin in phaffia rhodozyma; the method comprises the following steps: introducing a non-homologous terminal junction protein gene and an iron reductase gene into phaffia rhodozyma cells, cooperatively expressing the non-homologous terminal junction protein gene and the iron reductase gene, and fermenting by using the phaffia rhodozyma to produce the astaxanthin. According to the method disclosed by the invention, the biomass and the astaxanthin yield of the phaffia rhodozyma are improved by synergistically overexpressing the non-homologous terminal connecting protein and the iron reductase gene in phaffia rhodozyma cells; the phaffia rhodozyma high-yield astaxanthin strain is constructed through a gene overexpression technology, has the characteristics of genetic characters and stable astaxanthin fermentation yield, and is relatively high in feasibility.

The disclosure provides methods of treating a condition of the retina by administering an inhibitor of connexin 36 and / or an inhibitor of connexin 45 to a subject with a retinal condition. This disclosure further provides compositions for the treatment of a retinal condition which include an inhibitor of connexin 36 and / or an inhibitor of connexin 45.

The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

During aging, egg cells exhibit gradual loss of adherin complexes. The absence of connexin ultimately results in premature separation of sister staining monomers, resulting in aneuploidy. The inventors have designed an artificial adhesion system that binds staining monomers or chromosomes by forming complexes, thereby reducing the phenomena of premature separation of age-related sister staining monomers, e.g., in egg cells. The artificial adhesion system is a complex, and the aneuploidy risk is reduced by binding chromosomes or dyeing monomers. The complex comprises (I) one or more first proteins and (II) one or more second proteins wherein: (I) the first protein and (II) the second protein each comprise (i) a chromatin binding component, (ii) a protein binding region located at the N-terminus of the chromatin binding component, (Hi) a protein binding region located at the C-terminus of the chromatin binding component. The invention also includes nucleic acid molecules encoding the complexes. In addition, several in vitro methods associated with the complexes or nucleic acid molecules encoding said complexes also constitute part of the invention.